Researchers analyzed anonymized records from the Saxony Cancer Registry for patients diagnosed between 1 January 2018 and 5 August 2024. Patients were assigned to a pre-pandemic period before March 2020, an early pandemic period from March 2020 through September 2021, and a later pandemic period after September 2021. September 2021 was used as a pragmatic transition point to distinguish the initial disruption period from a later phase in which healthcare services were adapting to continued circulation of SARS-CoV-2; it did not mark the end of the pandemic.

The cohort included 1,051 patients diagnosed before March 2020, 829 diagnosed during the early pandemic period and 1,336 diagnosed afterward. Patients were 28 to 98 years old, with a mean age of 66.14 years. Men represented 69.4% of the cohort and had a mean age of 64.10 years at diagnosis, while women represented 30.6% and had a mean age of 70.77 years. Initial UICC stage was available for 3,101 patients, and the number evaluable for treatment intervals varied because each interval required the relevant dates to be documented.

The median interval from diagnosis to the first multidisciplinary tumor board was 17 days before the pandemic, 15 days during the early pandemic period and 15 days in the later period. Among 688 patients who underwent surgery without subsequent radiotherapy, the median interval from tumor board to surgery was 12 days, 8 days and 13 days across the same periods. For 582 patients who underwent surgery followed by radiotherapy, the corresponding medians were 14, 11 and 13 days. Global tests identified differences among the periods, and all significant pairwise treatment-interval effects were weak.

Initial UICC stage also differed among the three predefined periods. Stage IV disease accounted for 46.0% of patients with available staging data before the pandemic, 36.5% during the early pandemic period and 39.3% in the later period. The association between period and stage was weak, with a Cramér’s V of 0.065, and no significant difference was found between the two pandemic periods in the adjusted pairwise comparison. The stage distribution therefore did not provide evidence of a consistent shift toward more advanced disease during the early pandemic period.

The exploratory analysis by year of diagnosis confirmed that the temporal patterns were not linear. The proportion of stage IV disease fell from 48.1% in 2018 to 36.2% in 2020, rose to 42.1% in 2022 and declined to 35.5% in 2023. The median diagnosis-to-tumor-board interval fell from 20 days in 2018 to 15 days in both 2020 and 2021, rose to 18 days in 2022 and fell to 14 days in 2023. For surgery with subsequent radiotherapy, annual medians ranged from 9 to 15 days, with a significant global difference; only the 2019-to-2020 comparison remained significant after adjustment. The interval for surgery without subsequent radiotherapy did not differ significantly by year.

These results are consistent with broader reports of heterogeneous pandemic-related changes in oral and head and neck cancer care. A German oral cancer cohort reported a longer treatment delay and higher pathological T classification in the first pandemic year, whereas a German multicenter study found no clear increase in tumor stage and reported a trend toward shorter time to intervention during lockdown. The Saxony findings add regional registry evidence, but the retrospective design and weak effect sizes mean that the observed differences cannot be attributed to the pandemic itself.

The study also examined only the period after diagnosis. The registry data did not include symptom onset, first contact with a healthcare professional or the interval between initial presentation and histological diagnosis. Consequently, the absence of longer post-diagnostic intervals does not exclude disruption earlier in the diagnostic pathway, including reduced use of screening, preventive examinations and dental visits during the pandemic.

Several limitations further constrain interpretation. Only two complete pre-pandemic years were available, and 2024 data ended on 5 August, potentially leaving later treatment steps incompletely documented. Alternative period cut-offs could change group composition, while the registry cohort may not be directly generalizable to other German states or healthcare systems. Missing treatment dates may also have introduced selection bias through complete-case analysis. The findings therefore describe temporal associations in documented post-diagnostic care, not evidence that COVID-19 either improved or harmed oral cancer care.

Subject of Research: Temporal variation in UICC stage and post-diagnostic treatment intervals for oral squamous cell carcinoma in Saxony during the COVID-19 pandemic

Article Title: Temporal variation in initial UICC stage and post-diagnostic treatment intervals in patients with oral squamous cell carcinoma in Saxony before and during the COVID-19 pandemic

Article References: Stach, G., Lauer, G., Farahzadi, S., Schröder, T. A., & Buckova, M. (2026). Temporal variation in initial UICC stage and post-diagnostic treatment intervals in patients with oral squamous cell carcinoma in Saxony before and during the COVID-19 pandemic. Frontiers in Oncology, 16, Article 1770029. https://doi.org/10.3389/fonc.2026.1770029

Image Credits: AI Generated

DOI: 10.3389/fonc.2026.1770029

Keywords: oral squamous cell carcinoma, COVID-19 pandemic, cancer registry, UICC stage, treatment intervals, Saxony, tumor board, head and neck cancer, Temporal, variation, initial, UICC

At presentation, the patient had severe oral pain, dysphagia, ulceration and intermittent bleeding associated with a progressively enlarging left maxillary lesion. She had lost 5 kg over approximately two weeks, weighing 70 kg despite a body mass index of 26.7 kg/m², and had an Eastern Cooperative Oncology Group performance status of 3. The treating team clinically assessed frailty from her rapid weight loss, reduced intake, functional limitations and cardiovascular comorbidities; no validated frailty instrument or baseline frailty score was recorded, and the authors cautioned that improvement should not be equated with documented reversal of frailty.

Biopsy confirmed well-differentiated squamous cell carcinoma. Immunohistochemistry showed negative p16, positive epidermal growth factor receptor expression and a programmed death ligand 1 combined positive score of 70. Contrast-enhanced computed tomography showed an approximately 44 × 42 mm left maxillary lesion with adjacent facial soft-tissue extension and destruction of the anterior and inferior maxillary sinus walls. Multiple ipsilateral cervical nodes were enlarged and considered suspicious, and the pretreatment clinical stage was recorded as cT4aN1M0. The tumor was considered anatomically resectable, but immediate extensive surgery and flap reconstruction were deferred because of concerns about the patient’s limited physiological reserve.

Because cisplatin was considered unsuitable because of poor performance status, nutritional compromise, clinically assessed frailty and cardiovascular comorbidities, the multidisciplinary team selected a chemotherapy-free preoperative regimen. Treatment began on 16 October 2025 with pembrolizumab 200 mg every three weeks and nimotuzumab 200 mg weekly. The rationale included the tumor’s high PD-L1 combined positive score and EGFR positivity, although the report states that this biomarker combination does not establish a validated treatment-selection rule. Supportive care included nutritional support, analgesia, oral care, correction of fluid or electrolyte disturbances, cardiovascular optimization and functional prehabilitation as tolerated. No grade 2 or higher immune-related adverse events or infusion reactions were reported during the neoadjuvant period.

After two treatment cycles, oral pain had largely resolved and the patient could eat independently. Her weight increased from 70 to 75 kg, performance status improved from 3 to 1, albumin rose from 32 g/L to 38 g/L, prealbumin increased from 125 mg/L to 235 mg/L and C-reactive protein declined from 38 mg/L to 6 mg/L. These laboratory changes accompanied the clinical improvement, but the report notes that albumin and prealbumin are influenced by inflammation and are not stand-alone measures of nutritional status. The available measurements also do not demonstrate recovery of muscle mass.

Computed tomography restaging showed marked regression of the primary tumor and reduced cervical lymphadenopathy, reported as a partial response under RECIST 1.1. Following the improvement in nutritional and functional status, the patient underwent maxillectomy and left neck dissection of levels Ia–IV on 12 December 2025. Frozen-section margins were negative, and no flap reconstruction was performed. The stated considerations for omitting flap reconstruction included her advanced age and limited physiological reserve; the report does not provide detailed postoperative morbidity or objective functional outcomes.

Final postoperative pathology was reported as ypT0N0, with no metastatic carcinoma in any of the 32 dissected lymph nodes: 0/10 at levels Ia–Ib, 0/10 at level II, 0/4 at level III and 0/8 at level IV. One node showed necrosis and dystrophic calcification compatible with treatment effect. However, the pathological narrative also described scattered degenerative atypical epithelial clusters interpreted as regressed carcinoma, and the report states that the original slides and final pathology record require confirmation before the complete pathological response is regarded as unequivocally established. Pretreatment nodal involvement was suspected radiologically rather than confirmed by biopsy, so the 0/32 result does not by itself demonstrate clearance of histologically confirmed nodal metastases.

Based on the negative resection margins and absence of metastatic carcinoma in the dissected nodes, the multidisciplinary team did not recommend postoperative radiotherapy or cytotoxic chemotherapy. The patient received maintenance immunotherapy, which was ongoing at the last reported follow-up in September 2026, approximately nine months after surgery. Assessments were conducted at one, three and six months after surgery, and no recurrence was reported at the last follow-up. The short follow-up does not permit conclusions about survival benefit or durable disease control, and the single case cannot validate the omission of postoperative radiotherapy in other patients.

The report emphasizes that recovery of access to surgery was the principal educational value, rather than pathological response alone. Because tumor-directed treatment and supportive care were provided concurrently, their separate contributions to improved intake, weight and performance status cannot be determined. The case also does not show that the antibody combination was necessary for surgery to become feasible, establish the independent contribution of either drug, or support reducing surgical margins, omitting neck dissection or withholding indicated local treatment. The authors state that the bridge-to-surgery concept warrants prospective evaluation in carefully selected patients, with assessment of treatment completion, nutritional intake, physical function, time to surgery, operative morbidity, pathological response, postoperative treatment delivery and longer-term disease control.

Subject of Research: A case report of neoadjuvant pembrolizumab plus nimotuzumab as a bridge to surgery for oral squamous cell carcinoma in a frail 75-year-old patient.

Article Title: Neoadjuvant pembrolizumab plus nimotuzumab as a bridge to surgery in a frail elderly patient with maxillary gingival and palatal squamous cell carcinoma: a case report

Article References: Lin, Q., Shang, L., Guo, Z.-Z., Wang, F., Li, B., Cai, B., Feng, L., Zhang, H., Song, Z., Wu, Z., & Xi, Q. (2026). Neoadjuvant pembrolizumab plus nimotuzumab as a bridge to surgery in a frail elderly patient with maxillary gingival and palatal squamous cell carcinoma: a case report. Frontiers in Oncology, 16, Article 1993693. https://doi.org/10.3389/fonc.2026.1993693

Image Credits: AI Generated

DOI: 10.3389/fonc.2026.1993693

Keywords: case report, oral squamous cell carcinoma, neoadjuvant immunotherapy, pembrolizumab, nimotuzumab, frailty, maxillectomy, pathological response, Neoadjuvant, plus, bridge, surgery

Oral submucous fibrosis is characterized by collagen accumulation and extracellular matrix deposition in the oral mucosa. The review identifies lysyl oxidase as a key mechanistic link: increased copper can enhance this enzyme’s activity, promoting greater collagen cross-linking. This process is consistent with the fibrosis seen in the condition. The authors describe copper as a contributor to the pathological environment rather than as a proven independent cause of malignancy.

Copper may also influence the cellular conditions that accompany fibrosis. Evidence summarized in the review indicates that excess copper can induce oxidative stress and epithelial injury. Together, these changes may create a microenvironment favorable to malignant transformation. However, the magnitude of these effects can vary with copper concentration, and the available findings do not establish a simple dose-response pathway from oral submucous fibrosis to oral squamous cell carcinoma.

At moderate elevations in intracellular copper, studies have associated copper with increased cellular proliferation, metabolic activity, and angiogenesis in oral squamous cell carcinoma. These are cellular and tumor-associated observations, not proof that copper produces the same effects in every patient or clinical setting. The review further notes that higher copper concentrations can be cytotoxic, suggesting that copper may shift from supporting proliferation and tissue remodeling to damaging cells when its intracellular level becomes sufficiently high.

The central limitation is the scarcity of direct evidence for copper-driven malignant transformation of oral submucous fibrosis. Most of the proposed connections are drawn from separate lines of research concerning collagen cross-linking, oxidative stress, epithelial injury, cancer-cell behavior, and angiogenesis. The narrative-review method synthesizes this literature but does not itself test causation, quantify risk, or demonstrate that a particular copper concentration predicts cancer. The findings therefore support continued investigation of copper homeostasis as a possible research avenue, including the development of candidate biomarkers and therapeutic strategies that adjust copper levels, while those clinical applications remain to be established.

Subject of Research: Copper metabolism in oral submucous fibrosis and malignant transformation

Article Title: Dual facets of copper in the malignant transformation of oral submucous fibrosis: A narrative review

Article References: S, G. P., Bose, D., Thayalan, D., AE, N., Krishnan, R., & A, R. (2026). Dual facets of copper in the malignant transformation of oral submucous fibrosis: A narrative review. Molecular Biology Reports, 53(1), Article 1505. https://doi.org/10.1007/s11033-026-12663-4

Image Credits: AI Generated

DOI: 10.1007/s11033-026-12663-4

Keywords: copper metabolism, oral submucous fibrosis, oral squamous cell carcinoma, collagen cross-linking, lysyl oxidase, oxidative stress, malignant transformation, angiogenesis, fibrosis, narrative review, Dual, facets

The study, published in BMC Pharmacology and Toxicology, used several complementary measurements to characterize how the combination affected the cancer cells. In addition to the MTT viability assay, the researchers used Annexin V and propidium iodide staining to detect apoptosis, examined cell-cycle distribution and employed quantitative real-time PCR to assess expression of genes associated with apoptosis, resistance to apoptosis and inflammation. An oxidative-stress assay measured glutathione levels. OEC normal epithelial cells served as controls for the in vitro experiments.

Among the clearest findings was that ivermectin attenuated cisplatin-induced S-phase arrest in HN9 cells. Cisplatin alone increased the proportion of cells associated with S-phase arrest, while the combination reduced that response compared with cisplatin monotherapy. The combination was also associated with lower expression of the pro-apoptotic markers BAX and caspase-3 than cisplatin alone. These measured changes were consistent with the lower cytotoxicity observed in the viability assay. Together, the results show that ivermectin interfered with several cellular responses associated with cisplatin in this experimental model, rather than strengthening them.

The treatments also produced differential changes in two measures connected with inflammation and oxidative stress. Expression of tumor necrosis factor alpha, or TNF-α, and cellular glutathione levels varied across the single-drug and combination conditions. The researchers suggested that ivermectin’s antioxidant and anti-inflammatory properties may contribute to its antagonistic interaction with cisplatin. That proposed explanation was not isolated by the experiments, and the results do not establish which molecular process produced the antagonism. The study instead links the reduced cytotoxicity with attenuated S-phase arrest and diminished expression of pro-apoptotic markers while leaving the full mechanism unresolved.

These findings are limited to an in vitro study of one oral cancer cell line, with normal epithelial cells included as controls. The research does not demonstrate a clinical treatment effect, and it does not show how ivermectin and cisplatin would interact in patients. The authors stated that further investigations are needed to clarify the underlying molecular mechanisms and determine whether similar effects occur in other oral cancer models or in vivo settings. Within the tested HN9 cells, however, the evidence demonstrates that ivermectin reduced rather than amplified the cytotoxic, pro-apoptotic and cell-cycle-arresting effects associated with cisplatin.

Subject of Research: Antagonistic interaction between ivermectin and cisplatin in HN9 oral squamous cell carcinoma cells.

Article Title: When drug repurposing backfires: antagonistic effects of ivermectin on cisplatin therapy in oral cancer

Article References: Tantawy, R., Raafat, S. N., El-Gawish, A., & Ghalwash, D. (2026). When drug repurposing backfires: antagonistic effects of ivermectin on cisplatin therapy in oral cancer. BMC Pharmacology and Toxicology. https://doi.org/10.1186/s40360-026-01198-w

Image Credits: AI Generated

DOI: 10.1186/s40360-026-01198-w

Keywords: ivermectin, cisplatin, oral cancer, drug repurposing, drug antagonism, cell viability, apoptosis, cell-cycle arrest, oxidative stress, cancer cell lines, drug, repurposing

MicroRNAs are short, non-coding RNA molecules, typically twenty to twenty-four nucleotides in length, that do not encode proteins. Instead, they act as fine-tuners of gene expression, binding to complementary sequences in messenger RNAs and either promoting their degradation or blocking their translation into protein. A single microRNA can regulate dozens or even hundreds of target genes, which places these molecules at critical junctions in cellular control networks governing proliferation, apoptosis, differentiation, and the epithelial-mesenchymal transition that allows cancer cells to invade and spread. Because microRNAs are stable, easily measurable, and often released into circulating body fluids, they have attracted intense interest as candidate biomarkers for cancer detection, prognosis, and treatment monitoring. In oral cancer specifically, dozens of studies have catalogued dysregulated microRNAs, yet no microRNA-based test has entered routine clinical practice, a gap the authors of the new study explicitly set out to help close.

The study was designed as a single-centre case-control pilot investigation. The team collected sixteen tissue samples confirmed by histopathology as oral squamous cell carcinoma, along with sixteen histologically normal oral tissue controls. From each sample they extracted total RNA, reverse-transcribed it into complementary DNA, and quantified the two microRNAs of interest using quantitative real-time polymerase chain reaction. U6 small nuclear RNA served as the reference gene, and relative expression was calculated with the widely used 2^-ΔΔCt method. Rather than relying on a single statistical test, the researchers employed a robust analytical framework: group differences were assessed with the Mann-Whitney U test, effect sizes were reported as Hodges-Lehmann median differences with 95 percent confidence intervals, and diagnostic performance was explored through receiver operating characteristic analysis with bootstrap resampling and leave-one-out internal validation.

The headline result concerns hsa-miR-26a-5p. This microRNA was consistently upregulated in the tumour samples, with a Hodges-Lehmann ΔCt difference of 3.59 and a 95 percent confidence interval running from 3.02 to 4.19, a difference that was highly statistically significant at p less than 0.001. In practical terms, the expression values of hsa-miR-26a-5p completely separated the tumour samples from the normal controls in this dataset, yielding an area under the receiver operating characteristic curve of 1.000. In biomarker research, a perfect separation in any single dataset is a striking finding, but it is also one that experienced researchers treat with caution. Small cohorts, homogeneous sampling, and the particular composition of a study population can all produce apparently flawless discrimination that fails to replicate in larger and more diverse groups.

The authors themselves are careful on this point, and their restraint is one of the more notable features of the paper. The cohort consisted exclusively of advanced-stage disease, with all tumours classified as Stage III or Stage IV. Because no early-stage tumours were included, the perfect separation observed cannot be interpreted as validated diagnostic accuracy for detecting oral cancer in general, let alone for catching the disease at a curable early stage. The team therefore reports the separation descriptively, framing the result as a hypothesis-generating observation that warrants confirmation in larger, independent, and stage-diverse cohorts before any diagnostic application is considered. This kind of explicit boundary-setting is increasingly expected in biomarker pilot studies, where overstatement of preliminary findings has historically fuelled cycles of enthusiasm and disappointment.

The second microRNA examined, hsa-miR-21-5p, tells a more complicated story. This molecule is arguably the most intensively studied microRNA in oral oncology, with a substantial literature linking its overexpression to tumour progression, treatment resistance, and poor survival. In the present dataset, however, its behaviour was far less convincing. The Hodges-Lehmann difference was 1.21, with a 95 percent confidence interval of 0.26 to 1.99 and a p value of 0.012, indicating a statistically detectable but modest and inconsistent shift between groups. The area under the curve was 0.758, well short of the separation achieved by hsa-miR-26a-5p. The finding is a useful reminder that biomarker performance is context-dependent: a molecule that performs strongly in meta-analyses of circulating samples or in large multi-centre tissue panels may behave differently in a small, locally recruited cohort processed with a specific reference gene and analytical pipeline.

Equally informative is what the study did not find. Neither hsa-miR-26a-5p nor hsa-miR-21-5p showed any association with tumour stage, histological grade, patient age, or sex within this cohort. For a biomarker candidate, the absence of correlation with clinical parameters cuts both ways. On one hand, it suggests the microRNA signal may reflect tumour presence rather than tumour burden, which would be desirable for a detection marker. On the other hand, with only advanced-stage tumours represented, the analysis had little stage variation to work with, so the null result on stage association is more a limitation of the design than a substantive biological conclusion.

The biological literature offers plausible reasons why hsa-miR-26a-5p might matter in oral carcinogenesis. Prior work has implicated the miR-26 family in modulating cancer-related pathways in oral squamous cell carcinoma, including studies showing that miR-26a and miR-26b can restrain tumour progression by targeting signalling molecules such as PAK1 in tongue squamous cell carcinoma. Other research has reported that hsa-miR-26a-5p can influence the sensitivity of oral cancer cells to ferroptosis, an iron-dependent form of regulated cell death, by acting on the cystine transporter SLC7A11. The molecule has also been connected to epithelial-mesenchymal transition programs in head and neck cancer stem cells through its regulation of long non-coding RNA networks. The present study does not test these mechanisms directly, but its expression data are consistent with the idea that hsa-miR-26a-5p occupies a meaningful position in the molecular circuitry of the disease.

The practical significance of the work lies partly in its setting. The authors emphasize that reliable molecular markers are especially needed in resource-limited settings, where access to advanced imaging and specialist pathology is constrained and where oral cancer, driven largely by tobacco, areca nut, and alcohol use, imposes a heavy burden. Quantitative PCR assays for microRNAs are relatively inexpensive and technically accessible, which makes a tissue-based or eventually saliva-based microRNA test an attractive proposition for screening and triage in high-burden regions. The study was conducted at a single institution in southern India with institutional ethics approval and informed consent from all participants, and it was supported by seed money from the Vinayaka Mission’s Research Foundation, illustrating how modestly funded local research can still contribute meaningful data to a global biomarker effort.

For now, the appropriate conclusion is the one the authors themselves draw. hsa-miR-26a-5p emerges from this pilot as a robustly overexpressed molecule in advanced oral squamous cell carcinoma, deserving of serious follow-up, while hsa-miR-21-5p, in this particular dataset, did not live up to its reputation. The path forward is clearly laid out: larger, independent, multi-centre cohorts spanning early and late disease stages, ideally paired with matched normal tissue and, eventually, minimally invasive sample types such as saliva or blood. Only then will the perfect separation seen in these sixteen tumour samples be revealed as either a genuine biological signature or an artefact of a small and homogeneous study. Either outcome would be valuable, and this careful, statistically disciplined pilot provides exactly the kind of honest starting point that the long search for an oral cancer biomarker needs.

Subject of Research: Differential expression of the microRNAs hsa-miR-21-5p and hsa-miR-26a-5p in oral squamous cell carcinoma

Article Title: Differential expression of hsa-miR-21-5p and hsa-miR-26a-5p in oral squamous cell carcinoma: A Single Centre pilot study

Article References: Kaliamoorthy, S., Vinitha, G., Manickam, K., Kandasamy, V., Vedeswari, P. C., & Archana, S. P. (2026). Differential expression of hsa-miR-21-5p and hsa-miR-26a-5p in oral squamous cell carcinoma: A Single Centre pilot study. Molecular Biology Reports, 53(1), Article 1527. https://doi.org/10.1007/s11033-026-12712-y

Image Credits: AI Generated

DOI: 10.1007/s11033-026-12712-y

Keywords: oral squamous cell carcinoma, microRNA, hsa-miR-26a-5p, hsa-miR-21-5p, biomarker, qRT-PCR, ROC analysis, cancer diagnosis, non-coding RNA, pilot study, head and neck cancer, molecular biology

The study, published in the Journal of Cancer Research and Clinical Oncology, analyzed 329 patients with primary cN0 OSCC who underwent CT staging and neck dissection between 2011 and 2024. The researchers, led by Jannik Ketschau and Lucas M. Ritschl of the Department of Oral and Maxillofacial Surgery at TUM University Hospital Klinikum Rechts der Isar, set out to determine whether the time elapsed between the diagnostic CT scan and the operation had any measurable effect on pathological nodal outcome. The question is clinically important because staging CT scans are typically performed days or weeks before surgery, and if tumor cells were seeding new lymph node deposits during that window, one might expect longer intervals to correlate with higher rates of nodal positivity. The team also examined whether the interval influenced the total number of lymph nodes removed and the presence of extranodal extension (ENE), a feature in which cancer cells breach the lymph node capsule and which carries significant prognostic weight.

The median CT-to-surgery interval in the cohort was 9.0 days, with an interquartile range of 5.0 to 15.0 days — meaning most patients underwent surgery within roughly two weeks of their scan. Overall, 53 patients, or 16.1 percent of the cohort, had lymph node metastasis on final pathology. In the initial univariable analysis, the interval was associated with lymph node positivity, with an odds ratio of 1.031 per additional day (p = 0.035). On the surface, this suggested that each extra day between CT and surgery modestly increased the odds of finding occult nodal disease. However, when the researchers adjusted for age and smoking status — two well-established confounders in head and neck oncology — the association weakened and lost statistical significance (OR 1.027, p = 0.065). A similar pattern emerged for lymph node count, which showed a comparable but non-significant association (incidence rate ratio 1.027, p = 0.068).

The team then deployed a battery of sensitivity analyses to test whether the initially significant finding was robust. They stratified patients into quartiles of CT-to-surgery interval, excluded extreme intervals, and adjusted for lymph node yield — the total number of lymph nodes retrieved during neck dissection, which itself reflects surgical technique and can influence the apparent rate of nodal detection. The association with nodal positivity failed every test. Across interval quartiles, the relationship was essentially flat (p = 0.969). After excluding intervals longer than 30 days, the odds ratio dropped to 0.995 (p = 0.824), indicating no meaningful effect among patients operated on within a month of their scan. After adjustment for lymph node yield, the association was similarly non-significant (OR 1.015, p = 0.334). In other words, the initially significant unadjusted result was not a stable signal but a fragile one that dissolved under closer statistical scrutiny.

Yet the data contained one notable exception. Among the 13 patients whose CT-to-surgery interval exceeded 30 days, the rate of nodal positivity was dramatically higher than in those with shorter intervals — 53.8 percent versus 14.6 percent. This finding, while striking, comes with important caveats. The subgroup is small, and the retrospective design cannot determine whether the prolonged interval itself contributed to nodal spread or whether these patients’ delays reflected other factors — such as more complex clinical presentations, comorbidities requiring optimization, or logistical barriers — that independently correlated with more aggressive disease biology. The researchers were careful to note that this observation warrants further investigation rather than serving as definitive evidence that delayed surgery causes occult metastasis.

The interval was not associated with extranodal extension (p = 0.740), suggesting that even among patients who did have nodal disease, the time elapsed between CT and surgery did not appear to influence whether cancer cells had breached the lymph node capsule. Tumor localization within the oral cavity was likewise not associated with nodal positivity (p = 0.175), indicating that the site of the primary tumor did not systematically alter the relationship between interval and occult spread. These null findings add to the overall reassurance offered by the study: within the range of intervals typically encountered in clinical practice, the CT-to-surgery window does not appear to be a major driver of occult nodal disease or its most concerning features.

The technical approach underlying the study reflects contemporary standards in surgical oncology research. By using logistic regression for binary outcomes such as nodal positivity and negative binomial regression for count outcomes such as lymph node number, the researchers applied statistical models appropriate to the data structure. The inclusion of sensitivity analyses — quartile stratification, exclusion of extreme intervals, and lymph node yield adjustment — demonstrates the kind of methodological rigor increasingly expected in retrospective surgical studies, where unadjusted associations can easily mislead. The fact that the initially significant unadjusted result was confined to a small subgroup with substantially prolonged intervals, rather than being a consistent gradient across the full range of intervals, is a key interpretive point: it suggests that routine clinical delays of days to a couple of weeks are not strongly linked to occult nodal metastasis, while substantially delayed surgery remains an open question.

For clinicians managing cN0 OSCC, the study offers practical reassurance. The decision to perform an elective neck dissection in a clinically node-negative neck is already contentious, balancing the morbidity of the procedure against the risk of leaving hidden disease untreated. If the CT-to-surgery interval were strongly associated with occult metastasis, it would add urgency to surgical scheduling and potentially influence staging protocols. The Munich data suggest that, within typical intervals, this concern is not strongly supported — the interval is not a major independent risk factor for occult nodal disease. However, the finding that patients with intervals exceeding 30 days had substantially higher rates of nodal positivity — albeit in a very small subgroup — suggests that substantially delayed surgery may warrant closer attention, whether through repeat imaging, expedited scheduling, or heightened clinical vigilance.

The study also highlights the persistent limitations of CT-based staging in the cN0 neck. Despite advances in imaging technology, CT sensitivity for detecting small nodal deposits remains limited, and occult metastasis rates in cN0 OSCC continue to be clinically significant. The 16.1 percent rate of nodal positivity in this cohort — despite all patients having been staged as node-negative on CT — underscores this diagnostic gap. As imaging modalities evolve and molecular diagnostics advance, the hope is that the detection of occult disease will improve, reducing the reliance on elective neck dissection for patients whose nodal status remains uncertain. Until then, studies like this one provide valuable evidence about which clinical variables do — and do not — meaningfully influence the risk of hidden spread, helping surgeons and oncologists refine their approach to one of head and neck oncology’s most enduring challenges.

Subject of Research: CT-to-surgery interval and occult nodal metastasis in cN0 oral squamous cell carcinoma

Article Title: CT-to-surgery interval and occult nodal metastasis in cN0 oral squamous cell carcinoma

Article References: Ketschau, J., Mohr, J., Grabenhorst, A., Singer, H., Richter, H., Krautkremer, N., Niu, M., Pippich, K., Stimmer, H., Graf, M., Wolff, K.-D., & Ritschl, L. M. (2026). CT-to-surgery interval and occult nodal metastasis in cN0 oral squamous cell carcinoma. Journal of Cancer Research and Clinical Oncology. https://doi.org/10.1007/s00432-026-06642-2

Image Credits: AI Generated

DOI: 10.1007/s00432-026-06642-2

Keywords: CT-to-surgery, interval, occult, nodal, metastasis, oral, squamous, cell, carcinoma, scientific research

The study, led by Edoardo Mandalà and Martina Coppini, enrolled twelve patients at the Oral Medicine Unit of the Paolo Giaccone Policlinico University Hospital in Palermo, Italy. Seven had confirmed oral squamous cell carcinoma, while five served as cancer-free controls, including two healthy individuals and two with oral leukoplakia, a potentially precancerous condition. After one control patient was identified as a biological outlier because their microbial profile clustered suspiciously close to the cancer group, eleven subjects remained in the final analysis. From each participant, the team collected paired samples: unstimulated morning saliva and a fresh fragment of tissue taken during incisional biopsy, frozen immediately at minus 80 degrees Celsius.

The technical core of the study was next-generation sequencing of the 16S ribosomal RNA gene, the workhorse marker of microbiome science. This gene contains hypervariable regions that act like molecular barcodes, allowing researchers to identify which bacteria are present in a sample. The team targeted the V1, V2, and V3 hypervariable regions, amplified them by polymerase chain reaction, and sequenced the libraries on an Illumina MiSeq platform. After taxonomic classification using the Illumina BaseSpace 16S Metagenomics app, more than 1.2 million species-classified reads were retained across the 22 analyzed samples, averaging roughly 55,000 classified reads per sample. That depth allowed the researchers to identify 1,711 unique bacterial species distributed across 737 genera, providing an unusually fine-grained census of the oral ecosystem in health and disease.

The first surprise was that the total number of bacterial species did not differ dramatically between cancer patients and controls. Alpha-diversity analysis, which measures species richness and evenness within a sample, showed no significant differences in saliva and only a trend toward higher diversity in tumor biopsies. But when the researchers examined beta diversity, which compares the overall structure of microbial communities between samples, a different story emerged. In saliva, the communities of cancer patients and controls looked largely similar, with no distinct clustering. In biopsy samples, however, the two groups separated noticeably along the primary axes of a principal coordinate analysis based on Bray-Curtis dissimilarity, with a statistical trend approaching significance. The dysbiotic shifts associated with cancer, in other words, are far more pronounced inside the tissue microenvironment than in the saliva bathing it.

At the genus level, the core microbiome of the cohort was dominated by Streptococcus, which accounted for nearly a quarter of all sequencing reads, followed by Prevotella and Neisseria. But the distribution of these genera across the four study groups revealed a striking reorganization. In control saliva, Streptococcus reigned at 28 percent abundance, while in cancer patients’ saliva it dropped to 17 percent, nearly matched by an expansion of Neisseria to 17 percent from just 4.4 percent in controls. In tissue, the contrast was even sharper. Control biopsies were heavily dominated by Streptococcus at 37 percent, whereas cancer biopsies showed Streptococcus reduced to 22 percent alongside a marked rise of Fusobacterium, which climbed from 1.7 percent in healthy tissue to 7.4 percent in tumors.

Resolving these genus-level shifts to the species level produced the study’s most consequential findings. In tumor tissue, Fusobacterium nucleatum, an anaerobic bacterium already infamous for its role in colorectal cancer, exhibited a 29-fold increase in abundance, rising from a negligible 0.2 percent in control tissues to 4.9 percent in tumors, a difference that reached nominal statistical significance. This pathogen is no passive bystander. Previous research has shown that it stimulates cancer cell proliferation through the E-cadherin and beta-catenin signaling pathway and promotes immune evasion by binding the TIGIT inhibitory receptor on host immune cells. Meanwhile, health-associated commensals were systematically eradicated: Streptococcus salivarius, the most abundant species in control biopsies at 11.5 percent, plummeted to 0.3 percent in tumors, while Streptococcus oralis fell from 8 percent to 1.4 percent. These streptococci normally maintain oral homeostasis by producing bacteriocins and hydrogen peroxide, so their loss represents a functional collapse of colonization resistance, potentially opening the door for opportunistic anaerobes to invade.

The salivary signature told a complementary but distinct story. In cancer patients’ saliva, Neisseria macacae surged tenfold, from 0.9 percent in controls to 9.8 percent, becoming the single most abundant species in the cancer salivary microbiome. Concurrently, Haemophilus parainfluenzae and Neisseria perflava rose, while the commensal Streptococcus salivarius collapsed from 9.4 percent to 1.6 percent. This finding is particularly intriguing because it suggests that saliva, far from being a perfect mirror of the tumor, reflects a broader ecosystem shift that could be exploited for non-invasive screening. The researchers propose that the imbalance between Streptococcus and Neisseria in saliva might serve as a candidate biomarker, distinct from the intratumoral pathogen load that requires a biopsy to measure.

Perhaps the most forward-looking result came from an exploratory analysis of Fusobacterium nucleatum sequence variants. In five of seven cancer patients, the tumor niche was dominated by a single 16S sequence variant corresponding to reference NR_117842.1, which maps to the type strain ATCC 25586 of the subspecies nucleatum. This strain is the model organism for Fusobacterium pathogenicity, known to express high levels of the FadA adhesin that binds E-cadherin on epithelial cells and activates beta-catenin signaling. In patients with the highest bacterial burden, this single variant accounted for more than 99 percent of all Fusobacterium reads, suggesting an active selection process driven by the malignant microenvironment rather than passive colonization. One patient instead carried a distinct dominant variant mapping to the subspecies vincentii, indicating that while the specific strain may vary between individuals, the functional requirement for a highly adhesive, virulent phenotype appears conserved. The authors caution that standard 16S sequencing lacks definitive strain-level resolution, so confirming true clonal expansion will require shotgun metagenomics or whole genome sequencing.

When the researchers mapped microbial profiles across the clinical disease continuum, from healthy mucosa through leukoplakia to early and advanced cancer, a staged ecological succession came into view. Fusobacterium remained at baseline levels in healthy tissue and leukoplakia lesions, then surged during early-stage tumors, reaching peaks of nearly 14 percent, before declining in advanced disease. Prevotella, by contrast, established a dominant presence in advanced-stage tumors, stabilizing at abundances above 10 percent. This pattern aligns with the driver-passenger model of tumor microbiology: Fusobacterium may act as an active driver in the initial phases of malignancy, anchoring itself to the nascent tumor through the Fap2 adhesin that binds Gal-GalNAc sugars overexpressed on transformed epithelial cells, while strict anaerobic passengers like Prevotella later colonize the hypoxic, necrotic core of the growing mass.

The authors are careful to frame these findings as hypothesis-generating rather than definitive. With only eleven analyzed subjects, the statistical power is limited, and several trends that appear biologically meaningful did not survive multiple testing corrections. The inclusion of leukoplakia patients in the control group adds biological heterogeneity, the lack of systematic periodontal indices precludes precise assessment of baseline dental health, and the cross-sectional design cannot establish whether microbial shifts cause cancer or merely accompany it. Yet the magnitude of the changes observed, particularly the 29-fold enrichment of Fusobacterium nucleatum in tumors and the near-total eradication of protective streptococci, provides a compelling preliminary signal. If validated in larger, longitudinal cohorts, this work could lay the foundation for a multi-marker diagnostic panel combining salivary microbial ratios with intratumoral pathogen quantification, and it adds momentum to a growing field exploring microbiome-based precision medicine in oncology, where engineered bacteria may one day be deployed to remodel the tumor microenvironment and enhance immunotherapy.

Subject of Research: Oral cancer tumors harbor a distinct dysbiotic bacterial ecosystem dominated by Fusobacterium nucleatum, while saliva shows a separate Neisseria-driven signature, according to a 16S rRNA sequencing pilot study.

Article Title: Analysis of 16S rRNA to evaluate taxonomic differences between salivary and intratumoral microbiota in patients affected by oral squamous cell carcinoma: a single-center pilot study

Article References: Mandalà, E., Coppini, M., Mauceri, R., Pizzo, M., Giammanco, G. M., Campisi, G., & Bonura, C. (2026). Analysis of 16S rRNA to evaluate taxonomic differences between salivary and intratumoral microbiota in patients affected by oral squamous cell carcinoma: a single-center pilot study. Frontiers in Bacteriology, 5, Article 1863255. https://doi.org/10.3389/fbrio.2026.1863255

Image Credits: AI Generated

DOI: 10.3389/fbrio.2026.1863255

Keywords: oral cancer, microbiome, Fusobacterium nucleatum, 16S rRNA sequencing, oral squamous cell carcinoma, tumor microenvironment, salivary biomarkers, dysbiosis, Analysis, rRNA, evaluate, taxonomic

The research team, led by Xueru Chen and Jincai Guo of Changsha Stomatological Hospital and Hunan University of Chinese Medicine, systematically searched PubMed, Embase, and Web of Science from database inception through March 2026. Their aim was deceptively simple: to determine whether serum levels of total cholesterol, triglycerides, high-density lipoprotein, low-density lipoprotein, and very low-density lipoprotein differ systematically between people diagnosed with oral cancer and cancer-free counterparts. Such a question matters because lipid measurements are cheap, routinely ordered, and already standardized in clinical laboratories worldwide, making them attractive candidates for inexpensive biomarkers if a reliable association exists.

The results were remarkably consistent across all five lipid fractions. Patients with oral cancer showed significantly lower total cholesterol, with a pooled mean difference of −24.82 milligrams per deciliter and a 95 percent confidence interval stretching from −30.42 to −19.23. Triglycerides dropped by a mean of −21.27 milligrams per deciliter, high-density lipoprotein by −7.48, low-density lipoprotein by −15.98, and very low-density lipoprotein by −4.78, with every comparison achieving a p value below 0.001. In practical terms, a person with oral cancer in these studies carried a lipid profile that looked, on average, measurably depleted across the board rather than skewed in one direction alone.

The statistical architecture behind these estimates deserves attention. The authors pooled mean differences using a random-effects model in Stata 18.0, an approach that assumes the true effect may vary from study to study because of differences in populations, laboratory methods, and disease stages. They complemented the primary pooled estimates with sensitivity analyses, which test whether the overall result depends heavily on any single study, and with publication bias assessments, which probe whether smaller or null studies may have gone unpublished and inflated the apparent effect. Meta-regression allowed the team to explore whether study-level characteristics could explain part of the variation in effect sizes, a technique that becomes essential when, as here, heterogeneity between studies runs high.

Why would cancer drain the blood of lipids? Several biological mechanisms, long discussed in the oncology literature, offer plausible explanations. Rapidly dividing tumor cells have voracious biosynthetic appetites, and cholesterol in particular serves as a structural raw material for building new cell membranes. Tumors may also scavenge lipids from circulating lipoprotein particles, effectively siphoning cholesterol and triglycerides out of the bloodstream. On top of this, cancer-associated inflammation suppresses the liver’s production of lipoproteins, and malnutrition, which is common among patients with oral cancers that interfere with chewing and swallowing, further depletes circulating lipid reserves. Reactive oxygen species, which are elevated in many tumor microenvironments, can also oxidize and degrade lipid particles, adding another route of depletion.

The direction of the association, however, remains the central unresolved question, and it is one the authors handle with appropriate caution. Case–control studies of this kind measure patients after diagnosis, so the lower lipid levels could be a consequence of the tumor rather than a pre-existing risk factor. Intriguingly, some older research has reported the opposite pattern, with higher premorbid cholesterol associated with lower cancer risk in certain cancers, fueling a long-running scientific debate about whether lipids are cause, effect, or both. The new meta-analysis cannot disentangle this temporality, and its authors are explicit that the findings suggest an association consistent with altered lipid metabolism in oral cancer, not a causal pathway running in either direction.

Geography presents another limitation that shapes how far the conclusion can travel. Every one of the 25 included studies was conducted in Asian populations, meaning the pooled estimates describe a genetically, dietary, and environmentally homogenous group. Lipid baselines differ across populations for reasons ranging from diet to body composition to genetics, so the magnitude of the observed depletion may not replicate in European, African, or American cohorts. The authors note this population homogeneity directly, urging that the results be interpreted cautiously and calling for multi-center, high-quality studies in more diverse settings before any clinical translation.

Heterogeneity, the statistical measure of disagreement between studies, was high enough that the pooled numbers should be read as broad summaries rather than precise constants. In a random-effects framework, high heterogeneity means individual studies reported effect sizes that vary substantially, which can stem from differences in how oral cancer was defined, whether patients were treatment-naïve, the specific assays used to measure lipids, or confounding by smoking, alcohol use, and body mass index, all of which independently influence both lipid levels and oral cancer risk. The Newcastle-Ottawa Scale, the standard quality-assessment tool for observational studies of this kind, was applied to judge the methodological rigor of each included study, but even well-scored case–control designs cannot eliminate the reverse-causation problem inherent to measuring biology after disease onset.

Still, the clinical imagination behind the finding is easy to understand. Oral squamous cell carcinoma, the dominant form of oral cancer, is often diagnosed late, particularly in regions where screening infrastructure is thin. A five-parameter lipid panel costs pennies relative to imaging or molecular diagnostics, and it is already drawn during routine workups. If longitudinal studies confirm that a falling lipid profile precedes or accompanies early disease, and if the magnitude of change proves discriminative enough to separate patients from healthy individuals with acceptable sensitivity and specificity, lipid trajectories could eventually earn a place alongside existing risk markers. The authors position altered lipid metabolism as a potential biomarker candidate warranting further investigation, a deliberately measured framing that stops well short of claiming diagnostic utility.

For now, the takeaway for clinicians and researchers is less about immediate practice and more about a research agenda. The consistent, statistically robust depletion of all five lipid fractions across 25 independent studies is itself informative: whatever drives the pattern is strong enough to surface repeatedly in diverse Asian cohorts with different laboratory standards. The next generation of studies, the authors argue, must be prospective, multi-center, and designed to measure lipids before diagnosis, to adjust rigorously for nutritional status and inflammatory burden, and to test whether the lipid signal tracks with tumor stage, treatment response, or survival. Until then, the message of this meta-analysis is that oral cancer leaves a visible fingerprint in the blood’s fat chemistry, and that fingerprint is now too consistent to ignore.

Subject of Research: The association between serum lipid profiles and oral cancer

Article Title: Association between lipid profile and oral cancer: a systematic review and meta-analysis of case–control studies

Article References: Chen, X., Liu, L., Hu, D., Zhang, Y., & Guo, J. (2026). Association between lipid profile and oral cancer: a systematic review and meta-analysis of case–control studies. BMC Cancer. https://doi.org/10.1186/s12885-026-17158-w

Image Credits: AI Generated

DOI: 10.1186/s12885-026-17158-w

Keywords: oral cancer, lipid profile, meta-analysis, cholesterol, triglycerides, HDL, LDL, cancer metabolism, biomarker, case-control studies, oral squamous cell carcinoma, hypolipidemia

The centerpiece of current clinical success is the immune checkpoint inhibitor class, particularly antibodies that block the programmed cell death protein 1 (PD-1) receptor and its ligand PD-L1. Under normal conditions, the PD-1 pathway acts as a molecular brake on T cells, preventing autoimmune damage; tumors exploit this brake by expressing PD-L1 to disable attacking lymphocytes. Landmark trials such as KEYNOTE-048 demonstrated that pembrolizumab, alone or with chemotherapy, could outperform the cetuximab-based EXTREME regimen as first-line treatment for recurrent or metastatic head and neck squamous cell carcinoma, while nivolumab showed survival benefits in the platinum-refractory setting. For oral squamous cell carcinoma (OSCC), the most common malignancy of the oral cavity, these agents have translated into meaningful survival extensions, and the review highlights that anti-PD-1 therapy is now firmly embedded in standard practice for recurrent and metastatic disease.

Perhaps the most consequential shift described in the review is the migration of immunotherapy from the late-stage setting into the perioperative arena. In locally advanced disease, where surgery and radiation remain the backbone of care, neoadjuvant checkpoint blockade given before surgery has produced remarkable pathological responses. A phase 2 randomized trial by Schoenfeld and colleagues showed that nivolumab, alone or combined with ipilimumab, could be safely administered to untreated oral cavity squamous cell carcinoma patients before resection. More recently, the KEYNOTE-689 trial of perioperative pembrolizumab in locally advanced head and neck cancer and the GORTEC 2018-01 NIVOPOST-OP phase 3 trial, which tested postoperative nivolumab added to cisplatin chemoradiotherapy in high-risk patients, have begun to define how checkpoint inhibition can be woven into curative-intent treatment. A randomized phase 2 trial from China further showed that neoadjuvant immunotherapy with or without chemotherapy improved outcomes in locally advanced OSCC, suggesting that earlier immune intervention may prevent micrometastatic seeding and reduce relapse.

Yet the biology of the tumor microenvironment (TME) imposes hard limits on these gains. The review devotes substantial attention to the immunosuppressive ecosystem that OSCC builds around itself. Regulatory T cells, which express CD25 and the transcription factor FoxP3, accumulate in the blood and tumors of OSCC patients and actively suppress antitumor immunity. Myeloid-derived suppressor cells, identified by markers such as CD11b, contribute to malignant progression and correlate with poor prognosis. Tumor-associated macrophages, particularly the CD163-positive M2-like subset, are associated with lymphangiogenesis, lymph node metastasis, and cancer stem cell maintenance. Each of these cell populations represents both a mechanism of immune evasion and a potential therapeutic target.

Cancer-associated fibroblasts (CAFs) add another layer of resistance. These stromal cells remodel the extracellular matrix into a dense, often hypoxic scaffold that physically excludes cytotoxic T cells from tumor nests, a phenomenon the review describes as immune exclusion. Hypoxia, driven in part by hypoxia-inducible factors HIF-1α and HIF-2α, further promotes angiogenesis, metabolic reprogramming, and chemo-resistance, and meta-analyses have linked HIF-1α overexpression to worse survival in OSCC. Altered extracellular matrix composition has been shown to correlate with an immunosuppressive microenvironment and disease progression, particularly in younger patients. The practical consequence is that even when checkpoint inhibitors release the brakes on T cells, those cells may never reach their targets in sufficient numbers, explaining why response rates in unselected OSCC populations remain modest.

Beyond checkpoint blockade, the review catalogs a wave of emerging modalities now under active investigation. Near-infrared photoimmunotherapy (NIR-PIT) conjugates an antibody, typically against EGFR, to a photoabsorbing dye; when activated by near-infrared light, the conjugate induces rapid and selective necrosis of targeted tumor cells while sparing adjacent normal tissue. Phase 1 and 2 studies of RM-1929 photoimmunotherapy in recurrent head and neck squamous cell carcinoma have demonstrated encouraging local control. Bispecific antibodies (BsAbs), engineered molecules that simultaneously bind a tumor antigen and an immune cell receptor, are another fast-moving area. Petosemtamab, an IgG1 bispecific targeting EGFR and LGR5, has shown clinical activity in advanced head and neck cancer, and cadonilimab, a PD-1/CTLA-4 bispecific, is being tested with neoadjuvant chemotherapy in locally advanced disease. Oncolytic viruses, which infect and lyse tumor cells while releasing antigens that prime systemic immunity, have been combined with pembrolizumab in the MASTERKEY-232 study using talimogene laherparepvec.

Adoptive cell therapies represent the most technologically ambitious frontier. Tumor-infiltrating lymphocyte (TIL) therapy, which involves harvesting, expanding, and reinfusing a patient’s own tumor-reactive T cells, has already earned accelerated FDA approval for melanoma as lifileucel, and a 2025 report in the Journal for ImmunoTherapy of Cancer described efficacy and safety of one-time autologous TIL therapy in recurrent or metastatic head and neck squamous cell carcinoma. Chimeric antigen receptor (CAR) T and CAR-NK cells, genetically engineered to recognize surface antigens such as ErbB family receptors, MUC1, and CD276, have shown preclinical activity against oral tongue squamous cell carcinoma, and an intratumoral pan-ErbB targeted CAR-T study (T4 immunotherapy) has reported interim results in head and neck cancer. T cell receptor (TCR)-engineered T cells targeting viral antigens such as HPV-16 E6 and E7 have produced complete tumor regressions in metastatic HPV-associated epithelial cancers, while neoantigen-specific and cancer-testis antigen targets like MAGE-C2 are being explored for HPV-negative tumors, which dominate the oral cavity.

The obstacles, however, are formidable. The review identifies tumor heterogeneity, inadequate immune cell trafficking, antigen escape, and manufacturing complexity as the principal barriers to durable responses. Solid tumors like OSCC present a hostile terrain for engineered cells, and antigen loss following CAR-T therapy can render treated tumors invisible to the infused product. The lack of reliable predictive biomarkers remains perhaps the most clinically frustrating gap: PD-L1 expression, tumor-infiltrating lymphocyte density, and HPV status all provide hints, but none reliably forecasts which patient will benefit. Notably, HPV-positive tumors tend to harbor inflamed immune microenvironments and respond better to anti-PD-1 therapy, whereas most oral cavity cancers are HPV-negative and immunologically cold. Combination strategies, from checkpoint inhibitors paired with radiotherapy, which can release tumor antigens and inflame the microenvironment, to dual durvalumab and tremelimumab in the DUTRELASCO neoadjuvant study, are being pursued precisely to convert cold tumors into hot ones.

The authors conclude that future progress will depend on biomarker-guided patient selection, rational combination regimens, and engineered cellular therapies capable of overcoming microenvironment-mediated resistance. Cytokine-based approaches are also re-emerging: the IRX-2 natural cytokine biologic completed the INSPIRE trial as neoadjuvant therapy for resectable oral cavity carcinoma and is being combined with durvalumab in recurrent disease. As the field moves toward personalized, multimodal immunotherapy, the message of this comprehensive synthesis is clear: the immune system can be mobilized against oral cavity tumors, but doing so reliably will require dismantling the tumor’s protective ecosystem as systematically as the first generation of immunotherapy dismantled its molecular brakes. For patients with a disease whose five-year survival has barely budged in decades, that systematic dismantling may finally change the trajectory.

Subject of Research: Immunotherapy strategies and tumor microenvironment resistance mechanisms in oral squamous cell carcinoma

Article Title: Immunotherapy for oral cavity tumors: recent advances, key challenges, and future perspectives

Article References: Sharipova, G., Amonov, S., Kim, A., Kenjayev, S., Masharipova, N., Maxkamov, Z., Shaniyazov, S., & Alimova, Z. (2026). Immunotherapy for oral cavity tumors: recent advances, key challenges, and future perspectives. Molecular Biology Reports, 53(1), Article 1718. https://doi.org/10.1007/s11033-026-12906-4

Image Credits: AI Generated

DOI: 10.1007/s11033-026-12906-4

Keywords: oral squamous cell carcinoma, immunotherapy, immune checkpoint inhibitors, PD-1, tumor microenvironment, CAR-T cells, tumor-infiltrating lymphocytes, bispecific antibodies, oncolytic viruses, neoadjuvant immunotherapy, cancer-associated fibroblasts, hypoxia

The research, led by Thinh Thi Kim Truong, Shinsuke Fujii and Tamotsu Kiyoshima of Kyushu University in Japan, together with collaborators in Finland, Germany and Japan, focused on ARL4C, or ADP-ribosylation factor-like 4C, a small GTP-binding protein that has emerged as a key player in oral cancer biology. The team’s central question was deceptively simple: how does a gene operating inside cancer cells manage to reprogram healthy stromal cells at a distance so that they begin producing a potent bone-destroying signal? The answer they uncovered involves a relay of inflammatory messages, culminating in the activation of the transcription factor RelA, the major subunit of the NF-kappaB family, inside the fibroblasts themselves.

To dissect the mechanism, the researchers took a systematic approach. They cultured stromal cells in the presence of conditioned medium harvested from oral squamous cell carcinoma cells, effectively exposing the stromal cells to the full cocktail of soluble factors that tumors release into their surroundings. They then performed comprehensive RNA sequencing on the exposed stromal cells and ran pathway enrichment analyses to identify which signaling programs had been switched on. Two pathways stood out with striking clarity: NF-kappaB and Stat3. Both are classic inflammatory and survival pathways, and their coordinated activation suggested that the tumor-conditioned medium was driving the stromal cells into a pro-inflammatory state rather than merely nudging them toward RANKL production through a single linear signal.

The team then moved from observation to causation. Using small interfering RNA to knock down specific gene products, along with pharmacological inhibitors targeting candidate pathways, they tested which of the activated programs was actually required for RANKL induction. The result was unambiguous: blocking RelA, the principal DNA-binding subunit of NF-kappaB, significantly reduced the tumor-induced expression of RANKL in the stromal cells. In other words, without RelA, the fibroblasts exposed to tumor secretions no longer became efficient producers of the osteoclast-activating ligand. This positioned RelA not as a passive correlate but as the critical molecular gatekeeper through which the tumor’s influence on stromal RANKL flows.

With the stromal side of the axis mapped, the investigators turned to the tumor side, and this is where ARL4C entered the story. When the researchers manipulated ARL4C expression in the oral cancer cells, they found that the oncogene promoted the secretion of proinflammatory cytokines from the tumor cells. These cytokines, in turn, established a sustained, RelA-mediated inflammatory response in the stromal fibroblasts. The picture that emerges is a two-step relay: ARL4C inside the cancer cell drives the release of inflammatory messengers, and those messengers travel across the tumor-stroma boundary to lock the fibroblasts into an NF-kappaB-dependent program that includes robust RANKL production. The fibroblasts, in this scheme, are not innocent bystanders but active participants, converted into what the authors describe as a critical, non-canonical source of RANKL driving jawbone destruction.

Crucially, the team did not rely on cell culture alone. They examined human clinical specimens of oral squamous cell carcinoma using immunohistochemistry, the technique that allows specific proteins to be visualized in their tissue context. The staining revealed that phosphorylated RelA, the activated form of the transcription factor, and RANKL were co-expressed in stromal fibroblasts marked by alpha-smooth muscle actin, or alpha-SMA, a signature of activated cancer-associated fibroblasts. These double-positive cells clustered at the bone-invasive front of the tumor, the very frontier where cancer meets bone and where resorption is most aggressive. Perhaps most strikingly, the signal was detected even in areas distant from the tumor nests, indicating that the inflammatory instruction to produce RANKL can propagate through the stroma beyond the immediate vicinity of the cancer cells, potentially explaining why bone destruction in these tumors can be so extensive.

The identification of alpha-SMA-positive fibroblasts as the RANKL-producing population carries significant implications for how scientists think about cancer-induced bone disease. Much of the classical work on RANKL in bone metastasis has focused on osteoblasts, the bone-forming cells that normally express RANKL as part of the bone remodeling cycle, or on immune cells such as activated T lymphocytes. The new findings add stromal fibroblasts to that roster and suggest that in oral cancer, the tumor does not simply co-opt the normal remodeling machinery; it actively manufactures a new population of RANKL-secreting cells from the connective tissue it invades. This non-canonical route may help explain the particularly aggressive and locally destructive behavior of oral squamous cell carcinoma compared with tumors that metastasize to bone through the bloodstream.

From a therapeutic standpoint, the study points to the ARL4C-RelA axis as a potential target. If ARL4C in cancer cells is the upstream driver of cytokine secretion, and RelA in fibroblasts is the downstream executor of RANKL expression, then interrupting either node of the relay could, in principle, dampen the production of the osteoclast-activating ligand and slow or prevent jawbone destruction. The authors suggest that targeting this axis might represent a promising strategy for suppressing stromal RANKL expression and improving quality of life for patients with oral squamous cell carcinoma. Such an approach would complement existing antiresorptive treatments, which act on osteoclasts directly but do nothing to stop the tumor-driven signals that keep recruiting new bone-destroying cells. It is worth emphasizing, however, that the therapeutic implication remains a hypothesis grounded in preclinical experiments and human tissue correlation; clinical testing would be needed before any such strategy reaches patients.

The methodological rigor of the work deserves note as well. By combining unbiased transcriptomics with targeted perturbation, the researchers avoided the trap of assuming in advance which pathway mattered; the RNA sequencing pointed them toward NF-kappaB and Stat3, and only the inhibition experiments established that RelA was the indispensable component for RANKL induction. The pharmacological validation strengthens the case that the effect is druggable in principle, and the immunohistochemistry on patient specimens anchors the entire mechanistic story in human disease. The study was conducted in compliance with the Declaration of Helsinki, with ethical approval from the Kyushu University Research Ethics Committee, and the work received support from JSPS KAKENHI grants along with several Japanese and Finnish research foundations.

For the growing number of patients diagnosed with oral squamous cell carcinoma each year, jawbone invasion is one of the most feared consequences of the disease, driving extensive surgical resections and long-term functional impairment. By revealing that a single oncogene in the cancer cells can conscript neighboring fibroblasts into a bone-destroying role through a defined inflammatory pathway, this study transforms a poorly understood clinical phenomenon into a molecular circuit with named components and identifiable points of intervention. The next steps, the findings suggest, lie in exploring whether blocking ARL4C-driven cytokine release or RelA activation in the stroma can preserve bone in experimental models, and ultimately in determining whether patients whose tumors harbor high ARL4C expression might benefit from therapies aimed not at the cancer cells themselves but at the corrupted dialogue they conduct with the tissue around them.

Subject of Research: ARL4C-driven tumor-stroma inflammatory signaling and RANKL-mediated bone destruction in oral squamous cell carcinoma

Article Title: ARL4C in oral cancer cells promotes stromal RANKL expression via a RelA-dependent inflammatory axis in stromal fibroblasts

Article References: Truong, T. T. K., Fujii, S., Hasegawa, K., Matsumoto, S., Kurppa, K. J., Heikinheimo, K., Petersen, J., Li, A., Elenius, K., Jimi, E., & Kiyoshima, T. (2026). ARL4C in oral cancer cells promotes stromal RANKL expression via a RelA-dependent inflammatory axis in stromal fibroblasts. Journal of Cancer Research and Clinical Oncology. https://doi.org/10.1007/s00432-026-06620-8

Image Credits: AI Generated

DOI: 10.1007/s00432-026-06620-8

Keywords: oral squamous cell carcinoma, ARL4C, RANKL, RelA, NF-kappaB, stromal fibroblasts, osteoclastogenesis, jawbone destruction, tumor microenvironment, inflammatory cytokines, cancer-associated fibroblasts, bone invasion